Shots:
- The P- IIb/III ALLEGRO trial evaluates ritlecitinib {50/30mg, (with/out one month of initial treatment with ritlecitinib, 200 mg), 10mg, PO, qd} vs PBO in 718 patients aged ≥12yrs. with alopecia areata
- The trial met its 1EPs of improving scalp hair regrowth, patients with 30/50mg dose had ≤ 20% scalp hair loss @24wks., the safety profile of the therapy was consistent with previous studies
- Ritlecitinib is a JAK3/TEC inhibitor & is currently being evaluated for vitiligo, RA, CD, and UC. The therapy has received BTD from the FDA to treat alopecia areata on Sept’2018
Click here to read full press release/ article | Ref: Pfizer | Image: The Wall Street Journal
The post Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata first appeared on PharmaShots.
